Hailing the government's move, Surajit Pal, pharma analyst at Prabhudas Lilladher, says the aim of regulation is to prevent rampant use of antibiotics. He says Abbott is likely to be severely impacted by the move as it has around 15.4 percent exposure to fixed-dosed combinations.
Ipca Labs hopes to continue doing very well in H2FY14 especially in its India formulation business, says ED AK Jain. It is awating USFDA approvals for Indore SEZ which, the company feels will boost its business going forward.
AK Jain, ED, Ipca Labs told CNBC-TV18 that the start of the earnings for the company is very good and down the line maybe after Q2 it may revise the guidance.
AK Jain, ED, Ipca Labs says the company's pain management segment is doing ver well and it has leadership in rheumatoid arthritis with substantial market share. The company's Indore facility will start production in 2 months.
Last week, Ipca Laboratories reported net profit of Rs 87.89 crore for the quarter ending December 31, 2012 on the back of strong sales across domestic and international markets. AK Jain, ED, Ipca Laboratories told CNBC-TV18 that the margins are going to remain in the regions of around 32 percent plus.
Exectuive director of Ipca Labs AK Jain told CNBC-TV18 that Ipca Lanbs aims to grow by 18-20% in the domestic market in FY13.
Executive Director of Ipca Labs AK Jain tells CNBC-TV18 that they aim to grow exports by 20% in the second half of the current fiscal year.
AK Jain, the executive director of Ipca Labs, in an interview on CNBC-TV18, talks about the latest happenings in the company and sector.
AK Jain, ED, Ipca Laboratories in an interview with CNBC-TV18 said that the company has projected normal growth of around 18-20% for the whole year. But if it receives the much awaited USFDA approval then it can register much higher growth ahead.
In an interview with CNBC-TV18, AK Jain, ED of Ipca Labs said, "We are waiting for the US FDA to inspect our SEZ Indore plant. This product will be produced there so, till the time we get the approval for the plant we will not be able to take the commercial production of this product."